Spotlight on Coenzyme Q10 in scopolamine-induced Alzheimer’s disease: oxidative stress/PI3K/AKT/GSK 3ß/CREB/BDNF/TrKB
Journal of Pharmacy and Pharmacology · 2023
DOI: 10.1093/jpp/rgad048 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2023. Verfasst von Sally A Abuelezz und 1 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Department, Faculty of Medicine, Ain-Shams University, Cairo, Egypt. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-akt, Alzheimer Disease. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 91 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Objectives
Excess amyloid beta (Aβ) and oxidative stress (OS) are inextricable hallmarks of the neuronal damage associated Alzheimer’s disease. Aβ-induced cognitive and memory dysfunctions are mediated through different signalling pathways as phosphatidylinositol-3-kinase (PI3K) and their downstream intermediates including protein-kinase-B, known as Akt, glycogen-synthase-kinase-3β (GSK-3β), cAMP-response-element-binding-protein (CREB), brain-derived-neurotrophic factor (BDNF) and tropomyosin-related-kinase receptor-B (TrKB). The current work aims to investigate the protective potentials of CoQ10 against scopolamine (Scop)-induced cognitive disability and the contribution of PI3K/Akt/GSK-3β/CREB/BDNF/TrKB in the neuroprotection effects.
Methods
The chronic co-administration of CQ10 (50, 100 and 200 mg/kg/day i.p.) with Scop in Wistar rats for 6 weeks were assayed both behaviourally and biochemically. Key findings CoQ10 ameliorated the Scop-induced cognitive and memory defects by restoring alterations in novel object recognition and Morris water maze behavioural tests. CoQ10 favourably changed the Scop-induced deleterious effects in hippocampal malondialdehyde, 8-hydroxy-2ʹ deoxyguanosine, antioxidants and PI3K/Akt/GSK-3β/CREB/BDNF/TrKB levels.
Conclusions
These results exhibited the neuroprotective effects of CoQ10 on Scop-induced AD and revealed its ability to inhibit oxidative stress, amyloid deposition and to modulate PI3K/Akt/GSK-3β/CREB/BDNF/TrKB pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology Department, Faculty of Medicine, Ain-Shams University, Cairo, Egypt.
- Basic Medical Sciences Department, Faculty of Medicine, Faculty of Medicine, Galala University, Suez, Egypt.
ORCID-Profile: Sally A Abuelezz, Nevien Hendawy
Zitieren
APA
Abuelezz, S. A., & Hendawy, N. (2023). Spotlight on Coenzyme Q10 in scopolamine-induced Alzheimer’s disease: oxidative stress/PI3K/AKT/GSK 3ß/CREB/BDNF/TrKB. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgad048
Vancouver
Abuelezz SA, Hendawy N. Spotlight on Coenzyme Q10 in scopolamine-induced Alzheimer’s disease: oxidative stress/PI3K/AKT/GSK 3ß/CREB/BDNF/TrKB. Journal of Pharmacy and Pharmacology. 2023. doi:10.1093/jpp/rgad048
BibTeX
@article{Abuelezz2023,
author = {Abuelezz, Sally A and Hendawy, Nevien},
title = {Spotlight on Coenzyme Q10 in scopolamine-induced Alzheimer’s disease: oxidative stress/PI3K/AKT/GSK 3ß/CREB/BDNF/TrKB},
journal = {Journal of Pharmacy and Pharmacology},
year = {2023},
doi = {10.1093/jpp/rgad048}
}
EUVIMED